Clinical trials
Atrophy clinical trials
Below are recruiting atrophy clinical trials, each written for real people, not researchers. We’re tracking 267 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT06647641Recruiting
Genetics study for PSP, CBS, MSA, and related conditions
This study looks at genetic factors in people with PSP, CBS, MSA, or similar brain conditions, and also in their family members. It involves genetic testing to learn more about these diseases and may help find new treatments.
Boston, MassachusettsAges 35 years+ - NCT07047144RecruitingPhase 2
Apitegromab for infants with SMA under 2 years old
This study tests a new medicine called apitegromab for babies under 2 years old with spinal muscular atrophy (SMA). It looks at whether the drug can help with muscle strength and reaching motor milestones like sitting or rolling.
Phoenix, ArizonaAges Up to 2 years - NCT07024667Recruiting
Laser treatment study for vaginal atrophy symptoms
This trial tests a carbon dioxide laser (FemiLift) to see if it can help women with vaginal dryness, burning, itching, or pain during sex caused by menopause. It aims to improve symptoms without hormones.
HaderaAges 45–75 - NCT06970106RecruitingPhase 1/Phase 2
Study of PYC-001 eye injections for people with a type of inherited optic nerve disease
This trial tests a new medicine called PYC-001, given as an injection into the eye, for people with a specific genetic form of vision loss called autosomal dominant optic atrophy (ADOA). It aims to see if the treatment is safe and could help protect or improve vision.
Sydney, New South WalesAges 18 years+ - NCT07701863Recruiting
Vaginal dryness treatment study
This study tests a new treatment (F-GYN) to help with vaginal dryness and pain during sex. It aims to see if the treatment improves moisture and reduces discomfort.
BolesławiceAges 18 years+ - NCT06977269Recruiting
Brain stimulation safety study for spinal muscular atrophy
This trial tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) is safe and tolerable for people with spinal muscular atrophy (SMA). It may help improve muscle function by activating low motor neurons.
Kharkiv, Kharkiv OblastAges 12 years+ - NCT06765733RecruitingEarly Phase 1
Testing Aleeto for multiple system atrophy (MSA)
This trial tests a new treatment called Aleeto for people with a specific type of multiple system atrophy (MSA-P) who haven't responded well to standard Parkinson's medications. The goal is to see if Aleeto is safe and might help improve symptoms.
Beijing, Beijing MunicipalityAges 30–75 - NCT06562283Recruiting
Reproducibility of a fatigue test for spinal muscular atrophy
This study checks how consistent a fatigue test is for people with spinal muscular atrophy (SMA). It helps doctors better understand fatigue in SMA and may improve future care.
Saint-Etienne, FranceAges 6 years+ - NCT07444450RecruitingPhase 3
Study of salanersen for babies with SMA previously treated with gene therapy
This study tests a new medicine called salanersen in babies who have already received gene therapy for SMA. It aims to see if adding salanersen is safe and effective.
Flower Mound, TexasAges birth–7 months - NCT02194816Recruiting
Online survey study for people with Parkinson’s or Parkinsonism
This study looks at how changing certain factors over time relates to symptoms in Parkinson’s disease and related conditions. You may help researchers by completing longer online surveys every 6 months for 5 years.
Kenmore, WashingtonAges 19 years+ - NCT03217578Recruiting
Newborn screening for spinal muscular atrophy in Taiwan
This trial offers testing for spinal muscular atrophy (SMA) to newborns. It aims to identify SMA early so families and doctors can act sooner if results suggest the condition.
Kaohsiung CityAges birth–2 weeks - NCT05747261RecruitingPhase 1/Phase 2
Single-dose gene therapy for children with spinal muscular atrophy
This trial tests a one-time gene therapy given through a vein to add a working SMN gene in children with spinal muscular atrophy (SMA). It mainly looks at safety first, and also checks early signs that treatment helps the disease.
MinskAges Up to 8 months - NCT06169046RecruitingPhase 2
Clenbuterol for spinal and bulbar muscular atrophy
This study tests if clenbuterol (a medication that may help strengthen muscles) can improve symptoms in people with spinal and bulbar muscular atrophy (SBMA, also called Kennedy's disease). It compares clenbuterol to a placebo (a dummy pill) over several months.
Padova, PDAges 18–75 - NCT07805278Recruiting
Pregnancy registry for spinal muscular atrophy
This study is a registry that collects information from families who had a pregnancy where the baby was diagnosed with spinal muscular atrophy (SMA) before birth and received treatment during the pregnancy. The goal is to learn more about these cases to improve care and outcomes.
Memphis, TennesseeAges Any age - NCT06500754Recruiting
Persistent intestinal damage in celiac disease on strict diet
This study looks at why some adults with celiac disease still have damage to their small intestine even after strictly avoiding gluten. It aims to understand persistent villous atrophy and could help improve long-term care for people like you.
Terrassa, BarcelonaAges 20–80 - NCT07798700Recruiting
Biofluid research for brain and movement disorders
This study collects blood, spinal fluid, and other samples from people with brain or movement disorders, their family members, and healthy volunteers. The goal is to find better ways to diagnose and understand these conditions.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06394232RecruitingPhase 1/Phase 2
Testing a cell therapy for advanced dry AMD with geographic atrophy
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
Jālna, MaharashtraAges 50–100 - NCT07729982Recruiting
Study tracking vision changes in OPA1 optic atrophy
This study follows people with a genetic form of optic atrophy over time to understand how vision changes. It does not test a treatment but helps doctors learn more about the condition to improve care.
Munich, BavariaAges Any age - NCT07668804RecruitingPhase 1/Phase 2
Study of an eye implant for geographic atrophy from dry AMD
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
Hurstville, New South Wales (nsw)Ages 50 years+ - NCT07644013Recruiting
Multiple System Atrophy Registry Study in China
This study is collecting information from patients with multiple system atrophy (a rare neurological condition affecting movement and body functions), Parkinson disease, and healthy volunteers to better understand these conditions. By participating, you help doctors learn more about how these diseases develop and progress.
Beijing, Beijing MunicipalityAges 40–75 - NCT07606365RecruitingPhase 2
Testing a New Treatment for Geographic Atrophy
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
Bakersfield, CaliforniaAges 60 years+ - NCT07582042Recruiting
Vision testing in geographic atrophy treated with pegcetacoplan
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Salt Lake City, UtahAges 65–90 - NCT07579364Enrolling by invitation
Voice Outcomes After Vocal Cord Surgery
This study follows people who have had surgery to improve one-sided vocal cord paralysis or atrophy—a condition where one vocal cord doesn't move properly or has shrunk. Researchers track how well your voice works and your quality of life over 2 years after surgery.
La Jolla, CaliforniaAges 18 years+
Hear when a new Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atrophy?
- Yes. Clin2 currently lists 267 recruiting atrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.